Interviews

As the first CRISPR-based therapies draw closer to approval, the Flagship-backed biotech believes its gene writing tech is the ‘definitive’ genetic medicine platform.

Emerging Company Profile: US firm Peptilogics is advancing through the clinic with its lead orthopedic anti-infective drug candidate based on an AI platform that utilizes algorithms to improve peptide design.

The UK firm with a presence in Boston has just emerged but Pheon’s CEO Bertrand Damour tells Scrip that big pharma is already showing interest in its next-generation antibody-drug conjugate.

Ponda Motsepe-Ditshego, who leads Amgen’s clinical trial diversity efforts, admits they are in early stages but noted progress internally and externally at better representing diverse patient groups.

The Danish major’s head of development tells Scrip that as cardiovascular disease is very closely related to obesity and diabetes, Novo Nordisk has the expertise to thrive in the former.

The private French firm’s new global head of R&D oncology spoke with Scrip about its two-pronged oncology strategy and its high hopes for the advanced glioma candidate, vorasidenib, which may improve upon Tibsovo.

The funds will help advance biologic R&D, manufacturing and commercialization capabilities across Europe as the major pursues more sophisticated modalities, its global biologics head tells Scrip.

The French firm will use the funds to establish proof-of-concept for two gene therapy programs in a rare eye condition as it strives to become a world leader in ophthalmic genomic medicine, its CEO tells Scrip.

Indegene’s chief technology officer, Tarun Mathur, talks to Scrip about blockchain’s potential in a number of areas across pharma’s operations including the clinical supply chain and trials as well as its role in enabling improved trust in the healthcare data ecosystem.

From founding to the approval and commercial launch of its first innovative drug took Beijing-based biotech InnoCare just seven years. After a listing in Hong Kong, the firm is now heading to Shanghai after obtaining the green light for a second listing from the STAR board.

Inspired by the discovery of the phytochemical corynoline being a potential MYC synthetic lethality agent, Anticancer Bioscience has designed and identified preclinical candidates that could lead to first-in-class innovative drugs.

Eric Rubin, who heads up early oncology clinical development at Merck Research Laboratories, tells Scrip that it became clear very early on that Keytruda was something special.